Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation

Aim: localization of the new nomenclature of steatotic liver disease in Russian clinical practice.Key points. In 2023, international consensus decided to introduce a new nomenclature for steatotic liver disease. The article discusses the reasons for the change in nomenclature and the new terms adopt...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. L. Raikhelson, M. V. Maevskaya, M. S. Zharkova, V. R. Grechishnikova, S. V. Okovityi, T. A. Deeva, N. V. Marchenko, M. К. Prashnova, V. T. Ivashkin
Format:	Article
Language:	Russian
Published:	Gastro LLC 2024-05-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	steatotic liver disease non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease metabolic dysfunction-associated steatohepatitis metabolic dysfunction and alcohol associated steatotic liver disease
Online Access:	https://www.gastro-j.ru/jour/article/view/961
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of shear wave elastography and attenuation imaging for predicting life-threatening event in patients with metabolic dysfunction-associated steatotic liver disease
by: Yudai Fujiwara, et al.
Published: (2025-02-01)

Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017–2018
by: Bin Liang, et al.
Published: (2025-02-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-02-01)

Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
by: Kangjie li, et al.
Published: (2025-03-01)

Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk
by: Núria Granel, et al.
Published: (2025-02-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

MetALD: Clinical aspects, pathophysiology and treatmentKeypoints
by: Jordi Gratacós-Ginès, et al.
Published: (2025-02-01)

Dietary and lifestyle indices for hyperinsulinemia and odds of MAFLD in overweight and obese children and adolescents
by: Ali Nikparast, et al.
Published: (2025-02-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01)

Liver fibrosis and markers of endothelial function at metabolic syndrome and early disorders of carbohydrate metabolism
by: L. V. Chesnokova, et al.
Published: (2014-12-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Prevalence of non-alcoholic fatty liver disease at obesity and its interrelation with cardio-vascular disease and 2nd type diabetes mellitus risk factors
by: G. A. Melnichenko, et al.
Published: (2012-04-01)

Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity
by: I. V. Logacheva, et al.
Published: (2019-01-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study
by: M. V. Mayevskaya, et al.
Published: (2020-01-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)

Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities
by: Pei Pei Lau, et al.
Published: (2025-02-01)

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study
by: Hui Liu, et al.
Published: (2025-01-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)

Efficacy of silymarinum at chronic diffuse liver diseases
by: A. V. Matvieiev, et al.
Published: (2011-09-01)

Nonlinear relationship between hepatic steatosis index and reversion to normal glucose regulation in Chinese adults with prediabetes
by: Haiyong Zeng, et al.
Published: (2025-02-01)

Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case)
by: A. A. Driga, et al.
Published: (2010-11-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

Principles of effective out-patient diagnostics of diffuse liver diseases
by: Komova A. G., et al.
Published: (2014-11-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Chronic alcohol intoxication and liver diseases
by: A. I. Khazanov, et al.
Published: (2009-02-01)

Algorithm of management of patient with alcohol-induced liver disease
by: M. V. Mayevskaya, et al.
Published: (2011-02-01)

Phenotypes of Non-Alcoholic Fatty Liver Disease in Different Regions of the Russian Federation, Diagnostic and Therapeutic Approach in Clinical Practice
by: V. T. Ivashkin, et al.
Published: (2023-08-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

Ultrasound radiomics-based logistic regression model for fibrotic NASH
by: Fei Xia, et al.
Published: (2025-02-01)

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: A. E. Bagriy, et al.
Published: (2021-06-01)

Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres)
by: M. V. Mayevskaya, et al.
Published: (2020-05-01)

Diagnostic Effectiveness of Transforming Growth Factor Beta 1 in Assessing the Risk of Developing Graft Dysfunction in Liver Recipient Children
by: R. M. Kurabekova, et al.
Published: (2019-06-01)

Diastolic dysfunction of myocardium and change of <i>Q–T</i> interval at chronic hepatitis C
by: A. A. Konysheva, et al.
Published: (2012-11-01)